SCN9A gene therapy(Sangamo Therapeutics)

N/A

Report date: 2024/07/08 17:21:16

Base Information

Drug NameSCN9A gene therapy(Sangamo Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionSodium channel protein type IX alpha subunit modulators
TargetsSodium channel protein type IX alpha subunit
Therapy Area/IndicationsNeuralgia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSangamo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSangamo Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeuralgia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A